Press release
2025-2034 Acute Care Syndromic Testing Market Outlook: Key Drivers, Emerging Challenges, and Strategic Insights
Acute Care Syndromic Testing
What Will the Acute Care Syndromic Testing Industry Market Size Be by 2025?
The market size for acute care syndromic testing has experienced remarkable growth in recent times. The market, which was valued at $4.08 billion in 2024, is projected to increase to $4.59 billion in 2025, with a compound annual growth rate (CAGR) of 12.3%. Factors driving this growth during the historic period include heightened awareness of antimicrobial resistance, an upsurge in government spending on infectious diseases, escalated investment in the healthcare structure, a growing emphasis on syndromic testing, the broadening of telemedicine, and an increase in the prevalence of infectious diseases.
What's the Long-Term Growth Forecast for the Acute Care Syndromic Testing Market Size Through 2029?
The syndromic testing market for acute care is anticipated to expand significantly in the coming years, reaching a value of $7.39 billion in 2029 with a compound annual growth rate (CAGR) of 12.7%. This growth over the projected period can be linked to several factors such as increased instances of infectious diseases, higher demand for rapid diagnostic solutions, enhancement in healthcare services, the increasing application of multiplex syndromic panels, and a growing elderly population. Crucial trends predicted during the forecast period encompass the transition towards point-of-care testing, incorporation of cloud-based platforms, utilization of multiplex panels, the emergence of AI-powered tools, and the automation of syndromic testing.
View the full report here:
https://www.thebusinessresearchcompany.com/report/acute-care-syndromic-testing-global-market-report
What Are the Key Growth Drivers Fueling the Acute Care Syndromic Testing Market Expansion?
The escalation in the prevalence of infectious diseases is anticipated to boost the acute care syndromic testing market in the future. The rise of such diseases, prompted by detrimental microorganisms like bacteria, viruses, fungi, or parasites, escalates the need for effective prevention and treatment. These diseases can transmit among individuals, from animals, or the environment, and their prevalence is driven by elements like population growth, urbanization, international travel, resistance to antibiotics, and climate alteration. Acute care syndromic testing is employed in the identification of infectious ailments to hastily pinpoint pathogens and co-infections using multiplex molecular diagnostics, which facilitates targeted treatment protocols. For example, the UK based government organization, Health Security Agency, reported in February 2024 that the positivity rate of influenza exponentially rose to 16.6% in the fourth week of 2024, an increase from 14.0% the preceding week. Along with this, consultations related to Influenza-like illness (ILI) also climbed, reaching 9.8 per 100,000 people, as opposed to 7.5 per 100,000 the previous week. Furthermore, Influenza-related hospital admissions also escalated to 7.63 per 100,000, up from 5.12 per 100,000 the prior week. Hence, the ascending prevalence of infectious diseases is propelling the acute care syndromic testing market.
Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21078&type=smp
Which Fast-Growing Trends Are Poised to Disrupt the Acute Care Syndromic Testing Market?
Leading corporations in the acute care syndromic testing market are prioritizing technological improvements such as multiplex real-time polymerase chain reaction (PCR) technology to upgrade diagnostic precision, expedite pathogen identification, simplify laboratory processes, reduce response time, and enhance patient results via accurate and prompt treatment procedures. Multiplex real-time PCR technology, a sophisticated molecular diagnostic technique can simultaneously detect and measure multiple pathogens or genetic targets in a singular PCR reaction, thereby enhancing efficiency and precision in diagnosing diseases. To illustrate, in April 2023, QIAGEN N.V., a biotech research firm from the Netherlands, introduced QIAstat-Dx, a syndromic testing solution in Japan. This system includes a SARS-CoV-2 respiratory panel capable of detecting beyond 20 pathogens from a single specimen. Utilizing multiplex real-time PCR technology, it generates swift results with less labor compared to individual PCR tests. By the close of 2022, over 3,500 systems had been installed worldwide to aid in diagnosing respiratory, gastrointestinal, and meningitis-related issues. The system is accessible in more than 100 countries, thereby promoting global syndromic testing accessibility.
How Is the Acute Care Syndromic Testing Market Segmented?
The acute care syndromic testing market covered in this report is segmented -
1) By Disease Type: Respiratory Diseases, Gastrointestinal Diseases, Genitourinary Diseases, Tropical Diseases, Other Disease Types
2) By Sample Type: Blood, Urine, Biofluids, Stool, Swabs, Other Sample Types
3) By Target: Bacteria, Viruses, Fungi, Parasites
4) By End User: Hospitals, Clinical And Diagnostic Laboratories, Research And Academic Institutions, Other End Users
Subsegments:
1) By Respiratory Diseases: Influenza, Respiratory Syncytial Virus (RSV), COVID-19, Tuberculosis, Other Respiratory Diseases
2) By Gastrointestinal Diseases: Clostridium Difficile Infection, Norovirus, Rotavirus, Salmonella, Other Gastrointestinal Diseases
3) By Genitourinary Diseases: Urinary Tract Infections (UTIs), Sexually Transmitted Infections (STIs), Vaginal Infections, Other Genitourinary Diseases
4) By Tropical Diseases: Malaria, Dengue, Chikungunya, Zika Virus, Other Tropical Diseases
5) By Other Disease Types: Meningitis, Sepsis, Other Emerging Infectious Diseases
Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=21078&type=smp
Which Companies Are Leading the Charge in Acute Care Syndromic Testing Market Innovation?
Major companies operating in the acute care syndromic testing market are Siemens Healthineers AG, F. Hoffmann-La Roche Ltd, Thermo Fisher Scientific Inc., Danaher Corporation, Becton, Dickinson and Company, Seegene Inc., bioMérieux SA, Sysmex Corporation, Bio-Rad Laboratories Inc., QIAGEN N.V., Werfen, DiaSorin S.p.A., Quidel Corporation, Luminex Corporation, Biocartis NV, Microbiologics Inc., QuantuMDx Group Ltd., Curetis GmbH by OpGen Inc., Genetic Signatures Ltd., Applied BioCode Inc.
Which Regions Are Leading the Global Acute Care Syndromic Testing Market in Revenue?
North America was the largest region in the acute care syndromic testing market in 2024. The regions covered in the acute care syndromic testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21078
This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.
Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.
Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info
Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release 2025-2034 Acute Care Syndromic Testing Market Outlook: Key Drivers, Emerging Challenges, and Strategic Insights here
News-ID: 4220714 • Views: …
More Releases from The Business Research Company
Segment Evaluation and Major Growth Areas in the Personalized Testing and Supple …
The personalized testing and supplements sector is gaining remarkable traction, driven by advancements in technology and a rising consumer focus on tailored health solutions. As more individuals seek customized wellness options, this market is set to experience substantial expansion in the coming years. Here's an in-depth look at its current valuation, key players, significant trends, and the main market segments shaping its future.
Market Valuation and Expansion Forecast for Personalized Testing…
Top Players and Market Competition in the Skin Microbiome Industry
The skin microbiome market is emerging as a significant area of interest due to growing awareness about the critical role of skin health and innovative skincare technologies. As research advances and consumer preferences shift towards more natural and science-backed products, this market is set to undergo substantial growth. Let's explore the current market size, key players, driving factors, and upcoming trends shaping the skin microbiome industry.
Projected Expansion in the Skin…
Key Strategic Developments and Emerging Changes Shaping the Upadacitinib Market …
The upadacitinib market is poised for significant expansion over the coming years, driven by advances in treatment options and increasing awareness of autoimmune diseases. This report delves into the market's current size, key drivers, major players, and the emerging trends shaping its future trajectory.
Steady Growth Expected in Upadacitinib Market Size Through 2029
The market for upadacitinib is projected to reach $2.54 billion by 2029, growing at a robust compound annual…
Analysis of Key Market Segments Driving the Alzheimer's Disease Diagnostic Marke …
The Alzheimer's disease diagnostic sector is rapidly evolving as advancements in technology and healthcare infrastructure open new possibilities for early detection and personalized treatment. With rising awareness and innovative approaches, this market is poised for significant growth in the coming years. Let's explore the current market size, key drivers, leading companies, and emerging trends that are shaping this critical healthcare field.
Projected Market Size and Growth Trends in Alzheimer's Disease Diagnostics…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
